Spyre Therapeutics announces the pricing of a $350 million public offering of common stock, with plans to advance research and development across several therapeutic areas.
PUBLIC · SYREOct 06, 2026
Amount Raised
$350 Million
Round Type
Post-IPO Equity
BengaluruBiotechnologyHealth CareTherapeutics
Investors
StifelLeerink PartnersTD CowenJefferies
Description
Spyre Therapeutics has priced its public offering at $85.00 per share, expected to raise approximately $350 million in gross proceeds. The funds will support ongoing programs in Gastroenterology, Rheumatology, and Dermatology. The offering is set to close by October 7, 2026. Jefferies, TD Cowen, and others are managing the offering.
Company Information
Company
Spyre Therapeutics
Location
Bengaluru, Karnataka, India
About
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
Fundz sees it the moment Spyre Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BengaluruBiotechnologyHealth CareTherapeutics